Treatment of cancer pain of the head and neck by continuous intravenous infusion of high-dose morphine: Report of two cases

1990 ◽  
Vol 48 (4) ◽  
pp. 398-400 ◽  
Author(s):  
Yutaka Hashimoto ◽  
Manabu Takarada ◽  
Hiroaki Tanioka ◽  
Benjamin M. Rigor
2019 ◽  
Vol 35 (3) ◽  
Author(s):  
Jie Ni ◽  
Hui Jiang ◽  
Fang Wang ◽  
Long Zhang ◽  
Dujuan Sha ◽  
...  

Objective: To evaluate the clinical effects of continuous intravenous infusion with high-dose furosemide on early acute kidney injury (AKI) complicated with acute lung edema. Methods: Ninety patients who had been treated by furosemide at routine dose for 12 hour but with unsatisfactory outcomes were selected and subjected to continuous intravenous infusion with high-dose furosemide. The dose was adjusted according to hourly urine output. Serum levels of urea nitrogen, creatinine and potassium, pH, oxygenation index and mechanical ventilation time before and 6, 12, 24, 48 and 72 hour after treatment were compared. Results: The urine outputs before and 6, 12, 24, 48 and 72 hour after treatment were (10.71±1.81), (164.52±21.42), (189.71±29.61), (181.33±23.52), (176.82±24.80) and (164.52±18.91) ml/h respectively. Compared with data before treatment, the serum levels of urea nitrogen, creatinine and potassium significantly decreased while pH and oxygenation index significantly increased after six hour of treatment (P<0.05). After treatment, the kidney functions of 80 patients (88.9%) were completely recovered, without obvious adverse reactions. Conclusion: For patients with early AKI complicated with acute pulmonary edema who cannot be cured by diuretic agent at routine dose, high-dose furosemide increases urine output and improves success rate. doi: https://doi.org/10.12669/pjms.35.3.1012 How to cite this:Ni J, Jiang H, Wang F, Zhang L, Sha D, Wang J. Effect of continuous furosemide infusion on outcome of acute kidney injury. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.1012 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


2008 ◽  
Vol 42 (2) ◽  
pp. 135-136 ◽  
Author(s):  
D Caselli ◽  
O Ziino ◽  
A Bartoli ◽  
G Santangelo ◽  
F Vanadia ◽  
...  

1991 ◽  
Vol 15 (6) ◽  
pp. 435-440 ◽  
Author(s):  
Seah H. Lim ◽  
Colin P. Worman ◽  
Therese Callaghan ◽  
Andrew Jewell ◽  
Mark P. Smith ◽  
...  

2012 ◽  
Vol 15 (6) ◽  
pp. 719-722 ◽  
Author(s):  
Teruyuki Kajiume ◽  
Yasuhiko Sera ◽  
Ryuichi Nakanuno ◽  
Taemi Ogura ◽  
Shuhei Karakawa ◽  
...  

2012 ◽  
Vol 15 (3) ◽  
pp. 287-293 ◽  
Author(s):  
Sébastien Salas ◽  
Matthieu Frasca ◽  
Brigitte Planchet-Barraud ◽  
Benoît Burucoa ◽  
Monique Pascal ◽  
...  

2011 ◽  
Vol 34 (1) ◽  
pp. 8 ◽  
Author(s):  
Zhiguo Luo ◽  
Jianhua Chang ◽  
Ye Guo ◽  
Hui Yu ◽  
Fangfang Lu ◽  
...  

Purpose: The purpose of this study was to determine if a combination chemotherapy, using continuous intravenous infusion of fluorouracil (5-FU) in combination with split-dose cisplatin, in patients with recurrent or metastatic head and neck squamous-cell could improve previously reported clinical outcomes. Methods: Forty-two patients with recurrent or metastatic head and neck squamous-cell cancer were treated by cisplatin (25 mg/m2/day on days 1-3) and 5-FU (750 mg/m2/day for 120 hours; continuous intravenous infusion on days 1 through 5) with a cycle that repeated every 3 weeks. Results: Of the 42 patients, 8 (19.1%) showed complete response and 12 (28.5%) demonstrated a partial response, giving an overall response rate of 47.6%. Response rates were significantly different for patients undergoing initial treatment vs. re-treatment:73.6% (14/19) vs. 25.9% (6/23), respectively (χ2=9.45, P < 0.05). Median time to progression was 7.2 months and median overall survival was 13.7 months. The 1 year survival was 57.1%. Toxicity mainly included myelo-suppression, mucositis, nausea and vomiting. Conclusion: Chemotherapy with 5-FU by continuous intravenous infusion in combination with split-dose cisplatin is effective with a tolerable toxicity profile in patients with recurrent, or metastatic squamous-cell carcinoma of head and neck. The overall response was significantly higher in patients undergoing initial treatment in comparison with patients undergoing re-treatment after relapse.


Sign in / Sign up

Export Citation Format

Share Document